Senate misfires with prescription drug bill
Cost increases more driven by rising utilization than prices
By 
ON THURSDAY, the Massachusetts Senate passed another ill-considered piece of legislation, Senate Bill 2651, that would impose price controls on one of Massachusetts most important economic sectors, biopharmaceuticals. The bill is ill-considered because its authors assume, as they say in their press release, that the legislation is necessary because of “rapidly rising prescription drug costs.” This(...)